Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
Running, not enrolling · Phase 1
Conditions studied: Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I
In brief
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Key facts
- Study ID
- NCT05364073
- Run by
- ArriVent BioPharma, Inc.
- People needed
- 160
- Starts
- 2022-06-30
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-03-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- ArriVent Investigative Site — Prescott, Arizona, United States
- ArriVent Investigative Site — Sacramento, California, United States
- ArriVent Investigative Site — Whittier, California, United States
- ArriVent Investigative Site — Celebration, Florida, United States
- ArriVent Investigative Site — Detroit, Michigan, United States
- ArriVent Investigative Site — Houston, Texas, United States
- ArriVent Investigative Site — Fairfax, Virginia, United States
- ArriVent Investigative Site — Blacktown, New South Wales, Australia
- ArriVent Investigative Site — St Leonards, New South Wales, Australia
- ArriVent Investigative Site — Heidelberg, Victoria, Australia
- Arrivent Investigative Site — Edmonton, Canada
- Arrivent Investigative Site — Toronto, Canada
- Allist Investigative Site — Hefei, Anhui, China
- Allist Investigative Site — Beijing, Beijing Municipality, China
- Allist Investigative Site — Chaoyang, Beijing Municipality, China
- Allist Investigative Site — Chongqing, Chongqing Municipality, China
- Allist Investigative Site — Harbin, Heilongjiang, China
- Allist Investigative Site — Zhengzhou, Henan, China
- Allist Investigative Site — Zhengzhou, Henan, China
- Allist Investigative Site — Wuhan, Hubei, China
- Allist Investigative Site — Xuzhou, Jiangsu, China
- Allist Investigative Site — Nanchang, Jianxi, China
- Allist Investigative Site — Changchun, Jilin, China
- Allist Investigative Site — Jinan, Shandong, China
- Allist Investigative Site — Jinan, Shandong, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.